FDG-PET Use In Oncology Procedures Shows Promise, Limits - RSNA Studies
This article was originally published in The Gray Sheet
Executive Summary
Positron emission tomography (PET) in conjunction with the imaging agent F-18 fluorodeoxyglucose (FDG) holds promise as a less invasive alternative to existing options in the regional staging of patients with newly diagnosed melanoma, according to a study by Puneet Singha, MD, et al., University Hospital of Cleveland.